Articles On Global Health (ASX:GLH)

WA Insolvency Solutions reckons there are “multiple commercially viable claims against several defendants” involved with the former ASX cannabis startup, Melodiol Global Health, formerly Creso Pharma.

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

A recent report from VanEck Australia suggests that after two down years for healthcare stocks, emerging tailwinds could spark a rebound.  The report said healthcare stocks have lagged over this period, mostly due to potential US policy...

Strong clinical data can help biotechs secure lucrative licensing and partnership deals  Dimerix has four licensing deals for lead drug DMX-200 in rare kidney disease Platinum’s Global Health Sciences Fund manager Dr Bianca Ogden notes se...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

Melbourne biotech ENA Respiratory has raised $34 million (US$22.4m) in a Series B funding round to support the development of its virus-agnostic nasal spray, INNA-051, designed to boost the body’s natural defences against respiratory infect...

ASX crawls up just 0.17pc with 7 sectors lower Healthcare sharply lower as Trump threatens tariffs on pharmaceuticals Strength in resources and banks outweighs greater market losses   Markets take stock as tariffs fire back up After a pol...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

ASX rises 0.22pc after flat day of trade Earnings reports from big cap companies weighed heavy Gains and losses equalised after lunch for steady end to day ASX edges higher on earnings equilibrium It was another tale of heroes and villai...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

ASX lifts 0.33pc on healthcare sector strength CSL adds 2.4pc as UBS marks ASX healthcare sector as best EPS pick Chinese manufacturing data contracts, but shows signs of stirring   Are healthcare bulls returning? The ASX healthcare secto...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

The Western Australian Government is investing $3.3 million in specialised workforce training delivered by SafeSide Prevention.  SafeSide Prevention will bring its workforce training to Western Australia to help suicide prevention across...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

ASX drops below 8000 as tariffs send shockwaves Goodman, CBA and tech stocks take a beating Bitcoin drops back down under US$88k   The ASX took a pretty heavy hit on Friday, sliding down by 1.8% to its lowest point since September. For th...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

Highlights   MDGH gains FDA approval for moxidectin to treat river blindness.   Ghana becomes the first river blindness-endemic country to approve moxidectin.   MDGH’s cost-plus pricing ensures affordable treatment for underserved pop...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

In this interview Dale Gillham and small cap company director Rod North discuss what to look for in microcap stocks and what place they should have in an investor’s portfolio. They discuss success stories, risk vs reward, and, the challe...

Amplia CEO Dr Chris Burns and long-time scientific collaborator Professor Andrew Wilks have been awarded the 2024 Prime Minister’s Prize for Innovation The scientists were recognised for their breakthrough in developing momelotinib, a drug...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin ADELAIDE, South Australia, Oct. 9, 2024 /PRNewswire/ — BioCina Pty Ltd., a global en...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Birth rates decline as people choose careers and pets Global pet industry is benefitting from this, to grow significantly by 2030 Ethical investing could thrive in sustainable pet product demand   The conversation around motherhood is evo...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

The S&P/ASX 200 Information Technology sector rose ~8% in August, despite a volatile month for global markets Global X said the Nasdaq had mixed performance driven by a combination of positive and negative factors  Wisetech Global rose...

S&P/ASX 200 recovers from heavy volatility early in the month to finish up 0.47% in August S&P Dow Jones Indices said mid-caps led the gains putting them ahead of large and small caps YTD Larvotto Resources rose on the back of Chin...

THC gummies are becoming popular for their convenience and effects Bioxyne has produced Australia’s first GMP-certified cannabis gummies Bioxyne is expanding production to meet rising demand   Functional foods are growing in popularity as...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

S&P/ASX 200 had its best month of the year in July finishing up 4% to record high S&P Dow Jones Indices says large cap companies continued to lead the market in July Consumer discretionary and real estate topped July sector leaders...

ASX smacked after Wall Street sell-off sparked a red day around the world. ALL sectors lower on Friday. Yep… all 11 of them. Small caps led by Spacetalk and Alto Metals   The local benchmark index is wallowing back under 8,000 points,...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

ASX 200 ends 0.5pc lower after a difficult start to the week Energy Sector the worst of some poor to middling performances Small caps led by AuMake on news of a new deal in China   Last week’s record highs seem a distant memory for the...

Materials, Energy and Infotech dominate a sluggish day on Wednesday Booktopia collapses with a grim outlook for a final chapter ahead Some standout performances among the small caps, but who won?   The ASX 200 benchmark struggled to make...

Island Pharmaceuticals inks deal to develop a treatment for potentially deadly viruses like Ebola Amplia recruits key 26th patient in Phase 2a trial of new treatment for advanced pancreatic cancer  Melodiol Global Health records unaudited...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

S&P/ASX 200 rose 1% in June with large caps leading gains with mid, small and emerging companies lagging S&P/ASX 200 financials and consumer staples were the top performers in June with materials the biggest laggard Urea fertiliser...

Choppy day leaves the ASX 200 benchmark below zero, down -0.2pc Energy surges on news of a coal fire in Queensland, because that’s good for business everywhere else Small Caps winners’ list dominated by a $12 million boat sale by Wellard,...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Two independent appraisals value land and building owned by Melodiol’s Canadian subsidiary Mernova at between $10.4 – $12 million Appraisals follow strong revenue progress at Melodiol, with $21.6m in revenue delivered for FY23 ME1 inks de...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Mernova finalises additional product development activities across edibles, vapes and dabbers Agreements made with contract growers to supplement existing cannabis capacity given strong demand Q2 FY24 purchase orders of $1.56m to date, hi...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

ASX losses accelerate after sluggish retail sector updates  Baby Bunting, Temple & Webster, JB Hi-fi all under pressure on soft sales Alliance Nickel soars on fat federal grant   After opening modestly higher this morning, the ASX qui...

Melodiol’s Canadian subsidiary Mernova continues to make strong progress Mernova launching additional products across various Canadian provinces Mernova has received purchase orders of $1.3 million in strong start to Q2 FY24    Special Re...